Acetaminophen (APAP) is a commonly used analgesic and antipyretic drug. If APAP is used in high doses, liver necrosis and nephrotoxicity can occur in laboratory animals and humans (
1). The APAP induces an animal model of nephrotoxicity to evaluate the efficacy of new therapeutic agents.
Silymarin (SM) is extracted from the
Silybum marianum L. Gaertn (milk thistle) seeds. It is a flavonoid with various biological impacts, such as cardioprotective, hepatoprotective, and anticancer (
2-
5). The SM protects the kidney against toxicants, such as cisplatin, vancomycin, and methotrexate (
6-
8). However, low aqueous solubility, poor permeability, and extensive metabolism of SM limit its therapeutic usage.
Several protocols, such as incorporating microspheres, liposomes, nanocarriers, and poly(lactic-co-glycolic acid) (PLGA) nanoparticles, improved the bioavailability and solubility of SM. The PLGA is a nontoxic and biodegradable polymer appropriate for tissue engineering, gene therapy, and drug delivery (
9). The PLGA encapsulation effectively enhances the hepatoprotective effects of SM (
10).
The APAP causes damage to the mitochondrial membrane and releases cytochrome c in response to oxidative stress, causing apoptosis in target cells. The
BCL-2 family genes located in the inner mitochondrial membrane regulate the release of cytochrome c (
11). Two groups of pro-apoptotic and anti-apoptotic genes exist in the
BCL-2 family. The release of cytochrome c from the mitochondria into the cytosol is brought about by the pro-apoptotic proteins, such as Bax. The anti-apoptotic genes, such as
BCL-2 and
BCL-XL, cause the prevention of the release of cytochrome c into the cytosol and inhibition of apoptosis. Therefore, the ratio of
BAX to
BCL-2 was used to identify the inducing apoptosis in various cells (
12).